OECD Book: Innovation in Pharmaceutical Biotechnology - Comparing National Innovation Systems at the Sectoral Level (link)

April 11, 2006

Paris, 10 Apr 2006

What are the specific characteristics of innovation in pharmaceutical biotechnology? How do biopharmaceutical innovation systems in OECD countries perform and which policies are suitable to foster performance?

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries: Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries' performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process. Major systemic failures affecting the functioning of the biopharmaceutical innovation systems are identified. Based on rich evidence, the report draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

This study forms part of a larger effort to compare innovation processes in different industry sectors and technological fields to provide policy guidance and to more fully elaborate the national innovation systems (NIS) approach to policy making.

Table of contents

Foreword

Executive Summary (English) - available for free download

Note de synthèse (French) - available for free download

  • Chapter 1. Introduction

  • Chapter 2. Summary of Country Studies:
    • Belgium
    • Finland
    • France
    • Germany
    • Japan
    • The Netherlands
    • Norway
    • Spain
Chapter 3. Comparison of Performance in National Biopharmaceutical Innovation Systems

Chapter 4. Openness of the Biopharmaceutical Innovation System

Chapter 5. Comparison of Selected Demand-side Factors

Chapter 6. Structure, Dynamics and Performance in National Biopharmaceutical Innovation Systems

Chapter 7. Systemic Imperfections in Biopharmaceutical Innovation Systems

Chapter 8. Policy Implications

The full volume can be browsed on the OECD Online Bookshop.

Further information

Organisation for Economic Co-operation and Development
http://www.oecd.org
Item source

Already registered?

Sign in now if you are already registered or a current subscriber. Or subscribe for unrestricted access to our digital editions and iPad and iPhone app.

Have your say

Log in or register to post comments

Featured Jobs

Group Administrator CAMBRIDGE ASSESSMENT
Group Administrator, Assessment CAMBRIDGE ASSESSMENT
Item Bank Administrator CAMBRIDGE ASSESSMENT

Register to continue  

You've enjoyed reading five THE articles this month. Register now to get five more, or subscribe for unrestricted access.

Most Commented

Track runner slow off the starting blocks

Lack of independent working blamed for difficulties making the leap from undergraduate to doctoral work

A keyboard with a 'donate' key

Richard Budd mulls the logic of giving money to your alma mater

Quality under magnifying glass

Hefce's new standards regime will enable universities to focus on what matters to students, says Susan Lapworth

Woman tearing up I can't sign

Schools and universities are increasingly looking at how improving personalities can boost social mobility. But in doing so, they may be forced to choose between teaching what is helpful, and what is true, says David Matthews

Door peephole painted as bomb ready to explode

It’s time to use technology to detect potential threats and worry less about outdated ideas of privacy, says Ron Iphofen